Related Experiment Videos
Development of a Tier I screening battery for detecting endocrine-active compounds (EACs)
J C Cook1, M A Kaplan, L G Davis
1DuPont-Haskell Laboratory for Toxicology and Industrial Medicine, Newark, Delaware 19714, USA.
Regulatory Toxicology and Pharmacology : RTP
|August 1, 1997
Summary
A new screening battery using in vivo and in vitro methods can quickly and cost-effectively detect endocrine-active compounds (EACs). This approach prioritizes compounds for further study by assessing their potency and potential to disrupt development, reproduction, or cancer pathways.
Area of Science:
- Endocrinology
- Toxicology
- Biochemistry
Background:
- Endocrine-active compounds (EACs) pose risks to development, reproduction, and cancer.
- Existing methods for detecting EACs can be time-consuming and expensive.
Purpose of the Study:
- To develop a rapid, cost-effective, and predictive screening battery for EACs.
- To identify and prioritize compounds for further toxicological evaluation.
Main Methods:
- Utilized a combination of in vivo (male and female rat) and in vitro (yeast transactivation system) assays.
- Evaluated 15 known endocrine-active compounds as positive controls.
- Assessed endpoints for variability, stability, predictiveness, and dose dependency.
Main Results:
- The in vivo screens assess hormonal activity, estrogenic/antiestrogenic effects, and prolactin pathway alterations.
- The in vitro yeast transactivation system identifies agonists/antagonists for estrogen, androgen, and progesterone receptors.
- Parallel testing with built-in redundancy minimizes false-negative/positive responses.
Conclusions:
- A comprehensive in vivo/in vitro screening battery can effectively detect various types of endocrine toxicants.
- This approach provides a quick, cost-effective, and predictive method for prioritizing compounds for further study.